Search Results
Mar 19, 2026, 08:20 ET INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Mar 18, 2026, 09:05 ET LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION
standard of care or placebo effects.Industry Context for OI Drug DevelopmentOsteogenesis imperfecta is a rare genetic disorder affecting bone strengthNo FDA-approved therapies currently exist for OI treatmentBisphosphonates are used off-label as the current
More news about: Levi & Korsinsky, LLP
Mar 16, 2026, 14:59 ET RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Mar 16, 2026, 02:22 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 13, 2026, 09:31 ET DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 12, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 12, 2026, 04:25 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Mar 11, 2026, 09:19 ET RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Mar 10, 2026, 19:11 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 09, 2026, 17:59 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 06, 2026, 08:58 ET RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Mar 06, 2026, 03:25 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 05, 2026, 16:59 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP
Mar 04, 2026, 16:15 ET Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Mar 04, 2026, 09:00 ET LEVI & KORSINSKY, LLP: CHRONOLOGY OF EVENTS IN THE MEREO BIOPHARMA SECURITIES CLASS ACTION
impact of setrusumab on clinical fracture risk reduction." The complaint notes the two Phase 3 trials—ORBIT and COSMIC—targeted different age ranges of OI patients.Timeline of Alleged Disclosure FailuresApril 30, 2024: Enrollment completed; Ultragenyx CMO
More news about: Levi & Korsinsky, LLP
Mar 03, 2026, 16:10 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 03, 2026, 11:30 ET CME Group Reaches New Open Interest and Volume Records in Dairy Futures and Options
/PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced that its Dairy futures and options products set a new open interest (OI) record of 403,113 contracts on February 27. In addition, Dairy futures and options reached a new record monthly average daily volume (ADV) of 11,234
More news about: CME Group
Mar 02, 2026, 03:51 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
gave investors a falsely optimistic impression of its understanding of the effects of its drug candidate on patients with Osteogenesis Imperfecta ("OI"). The Company's failures were revealed by the Phase III ORBIT study in which it failed to achieve a statistically significant reduction in annualized
More news about: The Schall Law Firm
Feb 27, 2026, 09:09 ET RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Faruqi & Faruqi, LLP
Feb 27, 2026, 06:10 ET Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RARE
impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while also minimizing risk that patients in Ultragenyx' Phase III Orbit study would fail to achieve a statistically significant reduction in annualized
More news about: Robbins Geller Rudman & Dowd LLP
Feb 26, 2026, 23:03 ET MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit
investors with material information concerning their expected results for the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately reduce the annualized fracture rates of the tested
More news about: THE ROSEN LAW FIRM, P. A.
Feb 26, 2026, 18:26 ET RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit
Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to
More news about: THE ROSEN LAW FIRM, P. A.
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]" Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur
More news about: Pomerantz LLP